Rebif New Formulation (RNF) Quality of Life (QOL) Study

Inclusion criteria

• Subject with a relapsing form of MS; diagnosis of MS is in accordance with the McDonald criteria
• Subject currently taking Rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment
• Subject currently using Rebiject II and 29 gauge needle
• Subject is between 18 and 60 years old inclusive
• Subject is able to read and understand English
• Subject is willing to follow study procedures
• Subject has given written informed consent and signed HIPAA
• Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) Being post-menopausal or surgically sterile, or ii) Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (Confirmation required within 30 days prior to start of the study)

Exclusion criteria

• Use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. Receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's Rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable
• Subject receiving MS therapy in addition (i.e., combination therapy) to Rebif® within 3 months prior to study enrollment or at any time during study protocol.
• Subjects who have previously been on Rebif New Formulation (RNF).
• Subject with progressive forms of Multiple Sclerosis (MS).
• Subject with history of any chronic pain syndrome.
• Subject has any other disease apart from MS that could better explain the subjects signs and symptoms.
• Subject has complete transverse myelitis or bilateral optic neuritis.
• Subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1.
• Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1 (prior to enrollment).
• Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase > 2.5 times the upper limit of the normal values.
• Subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.
• Subject suffers from other current autoimmune disease.
• Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
• Subject is pregnant or attempting to conceive
• Visual or physical impairment that precludes completion of diaries and questionnaires.